ISHLT2024: Industry Symposia - Thursday

CareDx

Heart and Seek: A Case-Based Demonstration of Multi-Modal Molecular Tools’ Impact on Cardiac Transplant Surveillance

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

The symposium will be an interactive case discussion of the clinical approach to molecular diagnostic interpretation in the context of early routine acute cellular rejection surveillance. The moderator will take the audience through two separate cases in which surveillance HeartCare testing is done on a monthly basis during the first-year post-transplant and the panelists will describe their preferred course of action as it relates to performance of biopsies, repeat testing or adjustment in immunosuppression.

Moderator

Yasbanoo Moayedi, MD, University Health Network, Toronto, ON Canada

Speakers

Shelley Hall, MD, FACC, FHFSA, FAST, Baylor University Medical Center, Dallas, TX USA
Farhana Latif, MD, New York Presbyterian Hospital, New York, NY USA
Jeffrey Teuteberg, MD, Stanford University School of Medicine, Palo Alto, CA USA

CVRx

Integrating Barostim into a Comprehensive Heart Failure Program

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

Expert faculty panel will discuss unmet needs with guideline-directed medical therapy, and review the latest in clinical data, mechanism of action, and patient selection for the use of Barostim in patients with HFrEF. Panel and audience discussions will include device selection in class II/III heart failure patients, patient selection and post-implant management, Barostim procedure and patient care pathways, and real world strategies for incorporating Barostim into a comprehensive heart failure program.

Moderator

Eugene Chung, MD, The Christ Hospital Network, Cincinnati, OH USA
Jan Schmitto, MD, Hannover Medical School, Hannover, Germany

Program

Challenges and Unmet Needs with GDMT in HFrEF

Richa Gupta, MD, MPH, MedStar Washington Hospital Center, Washington, DC USA

Beyond BeAT-HF: Real World Experience with Barostim

Pujan Patel, MD, Advent Health, Raleigh, NC USA

Integrating Barostim into a Comprehensive Heart Failure Program

Dmitry Yaranov, MD, Baptist Medical Group, Memphis, TN USA

Natera

Challenges of Single Lung Transplant and the Value of dd-cfDNA

Primary Core Therapy: Lung | Primary Practice Area: Pulmonology

There are inherent, increased risks and challenges associated with single lung transplantation over double lung. It is a procedure typically reserved for older, more frail recipients because of the shorter operating time and less complex nature of the surgery. Yet despite the less complex surgery, the mean survival rate of single lung transplant recipients is only 4.7 years, almost half that of double lung recipients. SLT recipients also have a higher risk of acute cellular rejection (ACR) and chronic lung allograft dysfunction (CLAD). Standard of care to monitor and assess the health of the transplanted lung is through invasive transbronchial biopsy procedures (TBBx). Serious complication rates range depending on the center and study from 7- 46% in SLT recipients. This highlights an even greater need in the single lung population for noninvasive surveillance options. Donor derived cell free DNA (dd-cfDNA) has been validated in single and double lung transplants with emerging data in support of clinical utility. This symposium will focus on the recent data in support of dd-cfDNA usage in the single lung transplant population from the SLAM study.

Moderator

David Ross, MD, Natera, Austin, TX USA

Program

Single Lung Transplant Review of Indications / Challenges

Reinaldo Rampollo, MD, Cedars-Sinai, Los Angeles, CA USA

SLAM Data Presentation

Ambalavanan Arunachalam, MD, Northwestern Memorial Hospital, Chicago, IL USA

TransMedics

TransMedics National OCS Program (NOP) – Transforming the Standard of Care and Delivering Excellent Outcomes

Primary Core Therapy: Heart | Primary Practice Area: Cardiothoracic Surgery

This session will highlight clinical outcomes, the national program and logistics network related to the organ care system for heart & lung.

Moderators

David D'Alessandro, MD, Massachusetts General Hospital, Boston, MA USA
Brandon Guenthart, MD, Stanford University, Palo Alto, CA USA

Program

Second Annual Report from The OCS Heart Perfusion (OHP) Registry in the USA – Post-Approval Clinical Experience

Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT USA

OCS Lung Use – Delivering Program Volume Growth and Improved Transplant Outcomes

Gabriel Loor, MD, Baylor College of Medicine, Houston, TX USA

Significant Reduction in PGD Incidence Associated with OCS DCD Heart Transplant Recipients In Real World Clinical Experience – Potential NOP Impact on Outcomes

Mani Daneshmand, MD, Emory University, Atlanta, GA USA

Cardioprotective Effect of OCS Perfusion in 4 and 6 hours Preservation – Histopathological Results of Randomized Controlled Study

Anthony Demitris, MD, University of Pittsburgh Medical Center, Pittsburgh, PA USA
Farhan Zafar, MD, TransMedics, Inc., Boston, MA USA

Second Year Performance Review of The US National OCS Program (NOP) for Cardiothoracic Transplants

Waleed Hassanein, MD, TransMedics, Inc., Boston, MA USA